Skip to main content
Journal cover image

Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.

Publication ,  Journal Article
Fayanju, OM; Ren, Y; Greenup, RA; Plichta, JK; Rosenberger, LH; Force, J; Suneja, G; Devi, GR; King, TA; Nakhlis, F; Hyslop, T; Hwang, ES
Published in: Breast Cancer Res Treat
February 2020

PURPOSE: Inflammatory breast cancer (IBC) is an aggressive variant for which axillary lymph node (LN) dissection following neoadjuvant chemotherapy (NACT) remains standard of care. But with increasingly effective systemic therapy, it is unclear whether more limited axillary surgery may be appropriate in some IBC patients. We sought to examine whether extent of axillary LN surgery was associated with overall survival (OS) for IBC. METHODS: Female breast cancer patients with non-metastatic IBC (cT4d) diagnosed 2010-2014 were identified in the National Cancer Data Base. Cox proportional hazards modeling was used to estimate the association between extent of axillary surgery (≤ 9 vs ≥ 10 LNs removed) and OS after adjusting for covariates, including post-NACT nodal status (ypN0 vs ypN1-3) and radiotherapy receipt (yes/no). RESULTS: 3471 patients were included: 597 (17.2%) had cN0 disease, 1833 (52.8%) had cN1 disease, and 1041 (30%) had cN2-3 disease. 49.9% of cN0 patients were confirmed to be ypN0 on post-NACT surgical pathology. Being ypN0 (vs ypN1-3) was associated with improved adjusted OS for all patients. Radiotherapy was associated with improved adjusted OS for cN1 and cN2-3 patients but not for cN0 patients. Regardless of ypN status, there was a trend towards improved adjusted OS with having ≥ 10 (vs ≤ 9) LNs removed for cN2-3 patients (HR 0.78, 95% CI 0.60-1.01, p = 0.06) but not for cN0 patients (p = 0.83). CONCLUSIONS: A majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

February 2020

Volume

180

Issue

1

Start / End Page

207 / 217

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
  • Lymph Nodes
  • Inflammatory Breast Neoplasms
  • Humans
  • Female
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fayanju, O. M., Ren, Y., Greenup, R. A., Plichta, J. K., Rosenberger, L. H., Force, J., … Hwang, E. S. (2020). Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat, 180(1), 207–217. https://doi.org/10.1007/s10549-020-05529-1
Fayanju, Oluwadamilola M., Yi Ren, Rachel A. Greenup, Jennifer K. Plichta, Laura H. Rosenberger, Jeremy Force, Gita Suneja, et al. “Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.Breast Cancer Res Treat 180, no. 1 (February 2020): 207–17. https://doi.org/10.1007/s10549-020-05529-1.
Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, et al. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat. 2020 Feb;180(1):207–17.
Fayanju, Oluwadamilola M., et al. “Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.Breast Cancer Res Treat, vol. 180, no. 1, Feb. 2020, pp. 207–17. Pubmed, doi:10.1007/s10549-020-05529-1.
Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat. 2020 Feb;180(1):207–217.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

February 2020

Volume

180

Issue

1

Start / End Page

207 / 217

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
  • Lymph Nodes
  • Inflammatory Breast Neoplasms
  • Humans
  • Female
  • Combined Modality Therapy